Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

3179 PWToday Stories

Dainippon Sumitomo Acquires Sepracor for $2.6 billion

04 Sep 09

Dainippon Sumitomo Pharma, The Japanese drugs maker, has announced its decision to acquire the U.S pharma firm, Sepracor, in a bid to widen its international range and influence. Dainippon's decision to bid for the U.S. firm represents part of the company's wider growth strategy - with expansion into U.S. markets functioning as a core objective. The company's antipsychotic drug, Lurasidone, has shown increasing global potential in recent months - particularly in the States. In purchasing Sepracor, Dainippon has also acquired around 1300 U.S. sales staff. A move that the drugs maker says will grow its foreign revenue from 8% to 40% of the total figure. Indeed, as the healthcare climate in Japan continues to deteriorate - due to falling costs and increasing competition with generic firms - many Japanese firms are looking to acquire distribution networks in the States in an effort to grow profits.

In announcing the all-cash acquisition, Dainippon President, Masayo Tada said: "Sepracor has pursued growth through development of its unique pipeline and introduction of innovative pharmaceutical products to the market, a strategy that fits perfectly with our management philosophy". Adrian Adams, President and CEO of Sepracor, also welcomed the move.

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.